London, United Kingdom, October 06, 2010 --(PR.com
)-- Photodynamic therapy (PDT) is a non-invasive and increasingly popular procedure to assist with the treatment of a wide variety of skin concerns. Originating as a treatment for pre-cancerous skin lesions, extensive research and development has seen the procedure evolve to become an accepted and effective solution for acne and skin photodamage.
The use of a topical lotion to heighten the skin’s sensitivity to applied light is proven to greatly enhance the power of the light alone. Light Amplifier™ RX utilises the photosensitising properties of levulinic acid and bergamot. As the primary active, levulinic acid has the ability to selectively target and destroy abnormal cells when exposed to certain wavelengths of light. The inclusion of a patent-pending penetration enhancer delivers the active ingredients directly into the sebaceous gland to guarantee focused application of the light.
For the treatment of acne and for optimum acne management, Light Amplifier™ RX works to create an excess of oxygen which destroys anaerobic bacteria. This has significant long-term benefits for the skin including lowered sebum secretion, a vast reduction in inflammation and a minimised chance of acne-induced scarring.
Medik8 skincare professionals are currently being trained by distributors worldwide on the use of Light Amplifier™ RX with PDT.
Note to editors:
Medik8 is the skincare brand of UK biotechnology company Pangaea Laboratories Ltd.
Founded in 1999 by pharmacologist Elliot Isaacs, Pangaea has always maintained high standards of scientific research, and all their products are developed with the aim of delivering cutting edge cosmetic technology to the public.